Susan Irene Hershenson is a prominent inventor based in Newbury Park, California. She has made significant contributions to the field of pharmaceutical protein formulations, holding a total of 11 patents. Her work focuses on developing innovative solutions that enhance the stability and efficacy of protein-based medications.

Latest Patents

One of her latest patents is titled "Self-buffering antibody formulations." This invention provides self-buffering protein formulations that are suitable for both veterinary and human medical use. The formulations are designed to maintain a stable pH over extended periods, avoiding the disadvantages associated with conventional buffering agents. This innovation is particularly beneficial for the treatment of various diseases in human subjects. Another notable patent is "Composition and method for treating inflammatory diseases," which involves a protein that exhibits therapeutic effects on inflammation, specifically targeting IL-1-mediated inflammatory diseases.

Career Highlights

Susan works at Amgen Inc., a leading biotechnology company known for its focus on innovative therapies. Her role at Amgen has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout her career, Susan has collaborated with notable colleagues, including Thomas Charles Boone and Ellen Ngoi Yin Cheung. These partnerships have furthered her research and expanded the impact of her inventions.

Conclusion

Susan Irene Hershenson is a trailblazer in the field of pharmaceutical protein formulations, with a strong portfolio of patents that address critical medical challenges. Her innovative work continues to influence the development of effective treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.